5 Healthcare Stocks Billionaires Are Buying

Cepheid (NASDAQ:CPHD)

Of the 64 billionaires in our database, 6 were long Cepheid (NASDAQ:CPHD) at the end of the third quarter, having amassed $91.47 million worth of the company’s stock, compared to 2 billionaires in the second quarter who ended the period with $39.82 million positions in the California-based molecular diagnostics company. Recently, Danaher Corporation (NYSE: DHR) completed its $4 billion acquisition of Cepheid. Brian Taylor’s Pine River Capital Management owns 1.41 million shares of the company as of the most recent 13F report.

Baxter International Inc (NYSE:BAX)

Baxter International Inc (NYSE:BAX) shares were owned by 10 billionaires tracked by Insider Monkey at the end of the third quarter, compared to 7 a quarter earlier. At the end of September, these billionaires had owned $3.33 billion worth of Baxter’s stock. The Illinois-based company reported third quarter EPS of $0.58, better than the estimates of $0.45, while revenue totaled to $2.56 billion versus the consensus estimate of $2.55 billion. The company recently increased its full year 2016 sales growth outlook to 2% on a reported basis from the prior guidance of 1%-2%, and also upped its earnings guidance to $1.88 to $1.91 per diluted share from $1.69 to $1.74 per diluted share. Dan Loeb’s Third Point owns 51.90 million shares of the company as of the end of the third quarter.

Bristol-Myers Squibb Co (NYSE:BMY)

12 billionaires in our database were bullish on Bristol-Myers Squibb Co (NYSE:BMY) at the end of the third quarter, versus 9 billionaires a quarter earlier. Recently, the New York-based pharmaceutical giant said it received European Commission approval for its Hodgkin lymphoma drug Opdivo (Nivolumab). For fiscal 2017, the company expects EPS of $2.85-3.05, compared to the consensus estimate of $2.92. D. E. Shaw’s D E Shaw reported owning 7.28 million shares of the company at the end of the third quarter. The stock is down over 17% year-to-date.

Disclosure: None